Predictors of Mortality in Patients With Biopsy-Proven Viral Myocarditis: 10-Year Outcome Data.
Adult
Aged
Biopsy
Cause of Death
Contrast Media
Death, Sudden, Cardiac
Epstein-Barr Virus Infections
/ mortality
Female
Follow-Up Studies
Gadolinium
Genome, Viral
Herpesvirus 4, Human
/ genetics
Humans
Image Enhancement
Magnetic Resonance Imaging, Cine
/ methods
Male
Middle Aged
Myocarditis
/ diagnostic imaging
Myocardium
/ pathology
Parvoviridae Infections
/ mortality
Parvovirus B19, Human
/ genetics
Time Factors
biopsy
cardiovascular magnetic resonance
late gadolinium enhancement
mortality
myocarditis
viral
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
18 08 2020
18 08 2020
Historique:
pubmed:
14
8
2020
medline:
10
3
2021
entrez:
14
8
2020
Statut:
ppublish
Résumé
Background There is scarce data about the long-term mortality as well as the prognostic value of cardiovascular magnetic resonance and late gadolinium enhancement (LGE) in patients with biopsy-proven viral myocarditis. We sought to investigate: (1) mortality and (2) prognostic value of LGEcardiovascular magnetic resonance (location, pattern, extent, and distribution) in a >10-year follow-up in patients with biopsy-proven myocarditis. Methods and Results Two-hundred three consecutive patients with biopsy-proven viral myocarditis and cardiovascular magnetic resonance were enrolled; 183 patients were eligible for standardized follow-up. The median follow-up was 10.1 years. End points were all-cause death, cardiac death, and sudden cardiac death (SCD). We found substantial long-term mortality in patients with biopsy-proven myocarditis (39.3% all cause, 27.3% cardiac, and 10.9% SCD); 101 patients (55.2%) demonstrated LGE. The presence of LGE was associated with a more than a doubled risk of death (hazard ratio [HR], 2.40; 95% CI], 1.30-4.43), escalating to a HR of 3.00 (95% CI, 1.41-6.42) for cardiac death, and a HR of 14.79 (95% CI, 1.95-112.00) for SCD; all
Identifiants
pubmed: 32787653
doi: 10.1161/JAHA.119.015351
pmc: PMC7660832
doi:
Substances chimiques
Contrast Media
0
Gadolinium
AU0V1LM3JT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e015351Références
J Am Coll Cardiol. 2006 Nov 21;48(10):1977-85
pubmed: 17112987
J Am Coll Cardiol. 2018 Dec 18;72(24):3158-3176
pubmed: 30545455
Circulation. 2004 Mar 16;109(10):1250-8
pubmed: 14993139
J Am Coll Cardiol. 2012 Feb 28;59(9):779-92
pubmed: 22361396
J Am Heart Assoc. 2013 Nov 18;2(6):e000416
pubmed: 24249712
J Am Coll Cardiol. 2016 Nov 29;68(21):2348-2364
pubmed: 27884253
Circulation. 2009 Nov 24;120(21):2069-76
pubmed: 19901193
Eur Heart J. 2007 Jun;28(11):1326-33
pubmed: 17493945
J Am Heart Assoc. 2020 Aug 18;9(16):e015351
pubmed: 32787653
Circulation. 2008 Aug 5;118(6):639-48
pubmed: 18645053
J Am Coll Cardiol. 2010 Jun 8;55(23):2614-62
pubmed: 20513610
Clin Res Cardiol. 2016 Jan;105(1):37-52
pubmed: 26133158
J Am Coll Cardiol. 2017 Oct 17;70(16):1964-1976
pubmed: 29025553
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Circulation. 1999 Nov 9;100(19):1992-2002
pubmed: 10556226
J Cardiovasc Magn Reson. 2008 Jul 07;10:35
pubmed: 18605997
J Cardiovasc Magn Reson. 2014 Jan 26;16:14
pubmed: 24461053
J Am Coll Cardiol. 2012 May 1;59(18):1604-15
pubmed: 22365425
Circulation. 2006 Oct 10;114(15):1581-90
pubmed: 17015795
Circ Cardiovasc Imaging. 2013 Mar 1;6(2):165-6
pubmed: 23512779
Curr Cardiovasc Imaging Rep. 2015;8(3):6
pubmed: 25705323
Circulation. 2018 Sep 11;138(11):1088-1099
pubmed: 29764898
Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d
pubmed: 23824828
J Am Coll Cardiol. 2017 Oct 17;70(16):1977-1987
pubmed: 29025554
Heart. 2006 Mar;92(3):316-20
pubmed: 15923280